Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spruce: OGX-427 in untreated stage IV non-squamous NSCLC
NCT01829113Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Jul 2013
- Primary completion
- Apr 2017
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
A Phase 2 trial of apatorsen in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by SCRI Development Innovations. Started Jul 2013; status: completed.
02
Drugs
apatorsen
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT01829113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01829113.